1.
Journal of Addiction Medicine
; 14(4):E1-E3, 2020.
Article
in English
| EMBASE | ID: covidwho-2316483
ABSTRACT
The COVID-19 health crisis joined, rather than supplanted, the opioid crisis as the most acutely pressing threats to US public health. In the setting of COVID-19, opioid use disorder treatment paradigms are being disrupted, including the fact that methadone clinics are scrambling to give "take-home"doses where they would typically not. The rapid transition away from in-person examination, dosing and group therapy in an era of social isolation calls for adjustments to clinical practice, including emphasizing patient-provider communication, favoring new inductees on buprenorphine and leveraging technology to optimize safety of medication treatment. Copyright © 2020 American Society of Addiction Medicine.